Galen is pleased to announce a significant strategic development that marks an important step forward in our continued growth across the Nordic region.

POA Pharma Scandinavia AB, part of the Galen group of companies, has entered a new exclusive licence and supply agreement with our longstanding partner, Laboratorios Salvat, S.A. This agreement represents an important expansion of our ENT portfolio in the Nordics and further strengthens the collaborative relationship that has supported the success of both organisations over many years.

Speaking about the announcement, Galen’s Managing Director and President Dennise Broderick said: “Our relationship with Salvat has been built on many years of trust, shared ambition, and a deep commitment to improving patient outcomes. This new agreement is not only strategically important for our Nordic growth but also reflects the strength of our partnership and the value we place on working with organisations who share our vision for long‑term, sustainable success.”

This milestone reflects Galen’s ongoing investment in the Nordic region and our commitment to broadening our presence in key therapeutic areas. We are now progressing into launch planning, with preparations underway to bring this new addition to the Nordic ENT market in the next fiscal year.

Our strategic focus on long-term partnerships and sustainable growth remains central to Galen’s vision for the future. This latest development reinforces our ambition to expand our footprint across the region and continue providing value through high quality, evidence-based healthcare solutions.

We extend our sincere thanks to all colleagues and partners involved in bringing this agreement to fruition. Your dedication, expertise, and collaborative spirit continue to drive Galen forward and position us strongly for the years ahead.